NCT04892017
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT04892017
Title A Phase 1/2 Study of Inlexisertib (DCC-3116) in Patients With RAS/MAPK Pathway Mutant Solid Tumors
Recruitment Active, not recruiting
Gender both
Phase Phase Ib/II
Variant Requirements Yes
Sponsors Deciphera Pharmaceuticals LLC
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA

Facility Status City State Zip Country Details
Massachusetts General Hospital Boston Massachusetts 02114 United States Details
Washington University Siteman Cancer Center St Louis Missouri 63108 United States Details
Rutgers Cancer Institute New Brunswick New Jersey 08901 United States Details
Laura & Isaac Perlmutter Cancer Center at NYU Langone Health New York New York 10016 United States Details
Oregon Health and Science University Portland Oregon 97239 United States Details
Hospital of the University of Pennsylvania Philadelphia Pennsylvania 19104 United States Details
NEXT Oncology Austin Texas 78758 United States Details
The University of Texas MD Anderson Cancer Center Houston Texas 77030 United States Details
NEXT Oncology San Antonio Texas 78229 United States Details
University of Wisconsin Clinical Science Center Madison Wisconsin 53792 United States Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field